[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University Hospital Erlangen\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":100},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,70],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100619662","non-invasive-msot-examination-of-muscle-oxygenation-in-athletes-and-pad-patients-100619662",false,"NCT07347535","Non-invasive MSOT Examination of Muscle Oxygenation in Athletes and PAD Patients","Non-invasive Assessment of Skeletal Muscle Oxygenation in Athletes and Patients With Peripheral Arterial Disease Using Multispectral Optoacoustic Tomography During Standardized Physical Exercise","Inclusion Criteria:\n\n* Age ≥ 18 years (adults capable of giving consent)\n* Capacity to consent. The subjects are able to understand the information provided and give their written consent.\n* Belonging to one of the following cohorts:\n* Endurance athletes: at least 3× per week ≥ 60 minutes of intensive endurance training (e.g., running, cycling, swimming)\n* Strength athletes: at least 3× per week ≥ 60 minutes of intensive strength training without additional endurance training\n* Healthy control subjects: less than 2× per week \\\u003C 30 minutes of physical activity, no known vascular diseases\n* PAD patients: diagnosed peripheral arterial occlusive disease in Fontaine stage I or IIa Women of childbearing age with or without contraception may participate, as there are no risks of harm to the fetus.\n* Consent to pseudonymized data collection and storage in accordance with the GDPR.\n\nExclusion Criteria:\n\n* Age over 75 years\n* Minors (Age \\\u003C 18)\n* safety concerns on the part of the study physician, e.g., in the case of of: physical, mental or psychiatric illnesses, acute or chronic conditions that could jeopardise safety or data quality\n* Taking medications that could affect physical performance or physiological measurements (e.g., heart rate, oxygen uptake).\n* Pregnancy with known risks or complications (participation is possible in principle, but subject to individual medical review).\n* Refusal to participate or lack of informed consent.",true,"ALL","18 Years","75 Years",{"count":21,"type":22},60,"ESTIMATED","OBSERVATIONAL","The aim of the study is to present the quantitative differences in oxygenated hemoglobin in different cohorts.\n\nThis clinical study evaluates whether there is a correlation between measurements using multispectral optoacoustic tomography and the results of spiroergometry in the context of performance diagnostics.",[26],"PAD - Peripheral Arterial Disease",[28,29,30],"MSOT","PAD","Spiroergometry","NOT_YET_RECRUITING","2026-01-14",{"date":34,"type":35},"2026-01-16","ACTUAL",{"date":37,"type":22},"2026-01-01",{"date":39,"type":22},"2026-08-01",{"name":41,"class":42},"University Hospital Erlangen","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":52,"conditions":53,"keywords":58,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},"100592502","diagnostic-imaging-of-vascular-malformations-using-msot-and-ulm-100592502","NCT06994260","Diagnostic Imaging of Vascular Malformations Using MSOT and ULM","Multispectral Optoacoustic Tomography (MSOT) and Ultrasound Localization Microscopy (ULM) as Diagnostic Imaging for Lymphatic, Venous and Arteriovenous Malformations","Inclusion Criteria:\n\n* Confirmed vascular malformations (arteriovenous, venous, or lymphatic).\n* ≥18 years old and able to give their consent\n\nExclusion Criteria:\n\n* No imaging for diagnostic confirmation has been performed or is planned.\n* Lack of written consent\n* \\\u003C18 years old\n* Safety concerns of the study physician (a patient with physical, psychological, or psychiatric conditions that, in the opinion of the study physician, could compromise the patient's safety or the quality of the data, thereby making the patient an unsuitable candidate for the study).",{"count":51,"type":22},15,"This clinical study evaluates the efficacy and accuracy of Multispectral Optoacoustic Tomography (MSOT) and Ultrasound Localization Microscopy (ULM) for imaging and diagnosing vascular malformations (venous, arteriovenous, lymphatic). The study aims to enhance diagnostic precision and improve treatment planning through advanced non-invasive imaging techniques.",[54,55,56,57],"Vascular Malformation","Arteriovenous Malformation","Lymphatic Malformation","Venous Malformations",[54,59,55,56,28,60],"Venous Malformation","ULM","2025-06-20",{"date":63,"type":35},"2025-06-22",{"date":65,"type":22},"2025-08-01",{"date":67,"type":22},"2026-06-01",{"name":41,"class":42},1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":16,"sex":78,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":83,"studyType":23,"phases":4,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":69},"100565488","polycystic-ovarian-syndrome-pcos-biomarker-evaluation-study-100565488","NCT06642831","Polycystic Ovarian Syndrome (PCOS) Biomarker Evaluation Study","Polycystic Ovarian Syndrome (PCOS) in Human Adolescent and Young Adult Females - Biomarker Evaluation Study (PHOEBE)","PHOEBE","Inclusion Criteria:\n\n* Female subjects age 15-25 years\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Less than 1 years from onset of menarche\n* Use of hormonal contraceptives\n* Documented ongoing pregnancy\n* Major ovarian abnormalities, including subject with only one ovary, cysts and solid masses \\> 2 cm as detected by transvaginal ultrasound\n* Malignancy ( documented malignancy, documentation of current radiation therapy or chemotherapy in medical record)","FEMALE","15 Years","25 Years",{"count":82,"type":22},380,"1 Year","The purpose of the study is to validate recently identified biomarkers for the identification of PCOS in adolecent and young adult women.",[86],"Polycystic Ovarian Syndrome (PCOS)",[88,89,90],"PCOS","biomarker","adolescents","RECRUITING","2024-10-14",{"date":94,"type":35},"2024-10-15",{"date":96,"type":35},"2023-01-31",{"date":98,"type":22},"2027-03",{"name":41,"class":42},""]